이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Nordic Nanovector 과거 수익 실적

과거 기준 확인 0/6

Nordic Nanovector의 수입은 연평균 -4.6%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 11.8%의 비율로 증가했습니다. 매출은 연평균 98.8%의 비율로 감소해 왔습니다.

주요 정보

-4.6%

수익 성장률

12.6%

EPS 성장률

Biotechs 산업 성장	20.9%
매출 성장률	-98.8%
자기자본 수익률	-487.5%
순이익	n/a
다음 실적 업데이트	31 Aug 2023

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

Nordic Nanovector 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

OB:NANOV 수익, 비용 및 수입 (NOK Millions )
날짜	수익	G+A 비용
31 Dec 22	-311	79
30 Sep 22	-388	78
30 Jun 22	-434	85
31 Mar 22	-445	86
31 Dec 21	-441	84
30 Sep 21	-418	77
30 Jun 21	-402	74
31 Mar 21	-425	73
31 Dec 20	-417	70
30 Sep 20	-444	81
30 Jun 20	-450	85
31 Mar 20	-436	84
31 Dec 19	-434	87
30 Sep 19	-384	81
30 Jun 19	-366	77
31 Mar 19	-339	77
31 Dec 18	-338	70
30 Sep 18	-335	75
30 Jun 18	-345	76
31 Mar 18	-329	73
31 Dec 17	-294	75
30 Sep 17	-267	74
30 Jun 17	-243	69
31 Mar 17	-227	62
31 Dec 16	-236	57
30 Sep 16	-207	52
30 Jun 16	-207	51
31 Mar 16	-203	50
31 Dec 15	-173	48
30 Sep 15	-169	44
30 Jun 15	-118	32
31 Mar 15	-86	25
31 Dec 14	-64	17
30 Sep 14	-45	10
30 Jun 14	-38	8
31 Mar 14	-26	6
31 Dec 13	-17	4
31 Dec 12	-13	4

양질의 수익: NANOV 은(는) 현재 수익성이 없습니다.

이익 마진 증가: NANOV 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: NANOV 은(는) 수익성이 없으며 지난 5년 동안 연간 4.6% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 NANOV 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: NANOV 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( 3% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: NANOV 현재 수익성이 없기 때문에 마이너스 자본 수익률( -487.52% )을 갖습니다.

Nordic Nanovector 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Nordic Nanovector ASA to Report First Half, 2023 Results on Aug 31, 2023

Nordic Nanovector ASA to Report Q2, 2022 Results on Aug 31, 2022

Nordic Nanovector ASA to Report Fiscal Year 2020 Results on Mar 27, 2021

Nordic Nanovector ASA to Report Q2, 2021 Results on Aug 27, 2021

Recent updates

Nordic Nanovector ASA Approves the Appointment of Ludvik Sandnes as New Chairman

Nordic Nanovector ASA Announces Resignation of Jostein Dahle, Chief Scientific Officer and Co-Founder

Chairperson recently bought kr436k worth of stock

New major risk - Share price stability

Nordic Nanovector ASA Announces CFO Changes

Nordic Nanovector ASA Announces Resignation of Eddie Berglund from the Board Effect from January 19, 2023

No independent directors

Nordic Nanovector ASA Approves Board Changes

Nordic Nanovector ASA to Report First Half, 2023 Results on Aug 31, 2023

Nordic Nanovector ASA (OB:NANOV) agreed to acquire 100% stake in APIM Therapeutics AS from Sarsia Seed AS, Trond Mohn Stiftelsen, Norsk Innovasjonskapital (NIK) III Fund, and Investinor Direkte AS.

Nordic Nanovector ASA Announces Resignation of Solveig Hellebust, Jean Pierre Bizzari and Thomas Ramdahl from the Board

Can Nordic Nanovector (OB:NANOV) Afford To Invest In Growth?

Nordic Nanovector ASA Announces Executive Changes

Nordic Nanovector ASA to Report Q2, 2022 Results on Aug 31, 2022

Nordic Nanovector to Seek Regulatory Feedback Following Its Preliminary Review and Independent Data Evaluation of Paradigme, Its Phase 2B Trial with Betalutin in R/R Follicular Lymphoma

Nordic Nanovector ASA Provides an Update on PARADIGME, Its Phase 2b trial of Betalutin in R/R FL as a Result of Continuing Slow Recruitment

Nordic Nanovector ASA Publishes Highlights Synergistic Potential of CD37-Targeted Radioimmunoconjugate Humalutin

Price target decreased to kr26.00

Price target decreased to kr26.00

Insufficient new directors

Price target increased to kr31.00

Nordic Nanovector ASA Provides an Update on the Timeline for PARADIGME

Is Nordic Nanovector (OB:NANOV) In A Good Position To Invest In Growth?

Price target decreased to kr27.25

Nordic Nanovector ASA Provides Update on Paradigme, Its Phase 2B Pivotal Trial with Betalutin® in R/R Follicular Lymphoma

Chief Executive Officer Peter Braun has left the company

We Think Nordic Nanovector (OB:NANOV) Needs To Drive Business Growth Carefully

Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Nordic Nanovector ASA Announces Update from Archer-1 Phase 1B Trial of Betalutin® in Combination with Rituximab in 2L Follicular Lymphoma

Independent Director has left the company

Nordic Nanovector ASA Appoints Peter L. Braun as Chief Executive Officer, Effective 6 April 2021

Price target raised to kr28.25

Nordic Nanovector ASA Sees Significant Improvement in Patient Recruitment Rate in PARADIGME, its Single-Arm Phase 2 Pivotal Trial with Betalutin in R/R Follicular Lymphoma

New 90-day high: kr20.00

Nordic Nanovector ASA to Report Fiscal Year 2020 Results on Mar 27, 2021

Is Nordic Nanovector (OB:NANOV) In A Good Position To Invest In Growth?

Nordic Nanovector ASA to Report Q2, 2021 Results on Aug 27, 2021

Nordic Nanovector ASA Completes Patient Enrolment into Phase 1 Trial of Betalutin® in Diffuse Large B Cell Lymphoma

Price target lowered to kr21.00

Price target lowered to kr38.50

Nordic Nanovector ASA Completes Enrolment into Second Safety Cohort of Follicular Lymphoma Patients in Archer-1 Phase 1B Betalutin®/Rituximab Combination Trial

New 90-day low: kr14.85

Nordic Nanovector Asa Publishes Results of Preclinical Study Demonstrating Betalutin Reverses Tumour Resistance to Rituximab in NHL Disease Models

New 90-day low: kr16.83

Nordic Nanovector Launches A -2-Haematogical L Cancers

New 90-day high - kr27.90

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기